European marketing authorization granted to Eli Lilly's Taltz for psoriasis

US pharma major Eli Lilly (NYSE: LLY) announced on Tuesday that the European Commission has granted marketing authorization for Taltz (ixekizumab) for plaque psoriasis.

The monoclonal antibody has been authorized for moderate to severe cases of the disease among patients who are candidates for systemic therapy in the European Union, having been approved by the US Food and Drug Administration last month.

Andrew Hotchkiss, president of Eli Lilly’s European and Canadian operations, said: “Psoriasis is a serious, chronic disease, associated with significant comorbidities including heart disease. There is currently no cure. Lilly is excited to make ixekizumab available in the EU for physicians looking to provide a new treatment option for patients with moderate to severe plaque psoriasis.”